Device Radiation Therapy Devices

Eye90 Microspheres

Payments companies reported to CMS as associated with Eye90 Microspheres. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$274Kassociated payments (2023-2025)
60clinicians with associated payments
1company reporting

By year

2024 $6,557
2025 $267K

Payments reported as associated with Eye90 Microspheres, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Vascular & Interventional Radiology $147K
Diagnostic Radiology $125K
Radiation Oncology $666
Family Medicine $386
Radiological Physics $224
Surgery $193

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Eye90 Microspheres

These are the largest totals companies reported as associated with Eye90 Microspheres. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Mark Westcott New York, NY Diagnostic Radiology $100,292.92
Robert Lewandowski Chicago, IL Vascular & Interventional Radiology $30,562.77
Steven Citron Atlanta, GA Vascular & Interventional Radiology $25,726.52
Eric Wang Charlotte, NC Diagnostic Radiology $23,451.23
Rahul Patel New York, NY Vascular & Interventional Radiology $20,866.61
Suvranu Ganguli Boston, MA Vascular & Interventional Radiology $18,905.92
Ripal Gandhi Miami, FL Vascular & Interventional Radiology $15,174.38
Fred Moeslein Columbus, OH Vascular & Interventional Radiology $12,337.73
Jeremy Kim Charlotte, NC Vascular & Interventional Radiology $7,877.71
Charles Nutting Greenwood Village, CO Vascular & Interventional Radiology $6,184.53

Prescribed Eye90 Microspheres?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.